Immune-Onc Therapeutics Announces Presentation of IO-202 Pha

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Spain , Madrid , Palo Alto , California , United States , Ahmed Aribi , Charlene Liao , Linkedin , Product Service , European Hematology Association , Leukemia Lymphoma Society Therapy Acceleration Program , Drug Administration , National Cancer Institute , National Institutes Of Health , California Institute For Regenerative Medicine , Onc Therapeutics Inc , Division Of Leukemia , Onc Therapeutics Announces Presentation , Interim Data , Chronic Myelomonocytic Leukemia , Hematology Association , Onc Therapeutics , Annual Meeting , Interim Efficacy , Faction Data , Expansion Cohort , Myelodysplastic Syndromes , Track Designations , Drug Designations , Leukocyte Immunoglobulin Like Receptor , National Institutes , California Institute , Regenerative Medicine , Lymphoma Society Therapy Acceleration Program ,